Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (13989)	7/5/2000 4:47:56 PM
From: Oak Tree	Respond to of 17367

I agree with you. The last peptide immune enhancer I got into was a company called ABTI lost my shirt. Same kind of story. Well done phase III trials, showed some promise in subgroup analysis for patients with abdominal surgery for pancreas cancer (for some reason it didn't seem to work for colorectal cancer). Stock was a $20 stock, its now a $0.001 stock. This sounds unpleasantly similar. We are all hoping for some new class of antibiotics -- this isn't it I don't think. Good antibiotics are not iffy, they are clear cut.